menu
The global preventive vaccines market is projected to be worth USD 94 billion by 2030, growing at a CAGR of 10.7%, claims Roots Analysis
Although vaccines were solely responsible for the globaleradication of smallpox (1980) and polio (2015), several vaccine-preventablediseases, such as measles and mumps, are still a threat; COVID-19 has beenrecently added to the list

Although vaccines were solely responsible for the globaleradication of smallpox (1980) and polio (2015), several vaccine-preventablediseases, such as measles and mumps, are still a threat; COVID-19 has beenrecently added to the list

 

Roots Analysis is pleased to announce the publication of its recentstudy, titled, “GlobalPreventive Vaccines Market, 2020-2030”.

 

The report features an extensive study of the currentmarket landscape and future opportunities associated with the preventivevaccine domain. The study also features a detailed analysis of the key driversand trends related to this evolving segment of the pharmaceutical industry.Amongst other elements, the report includes:

§ A detailed assessment of the current market landscape,featuring clinical-stage preventive vaccines.

§ A competitiveness analysis of preventive vaccine developers,featuring insightful pictorial summaries and representations.

§ Elaborate profiles of the key preventive vaccine developers(shortlisted based on a proprietary criterion) across North America, Europe andAsia Pacific.

§ An in-depth analysis of the completed, ongoing and plannedtrials of various preventive vaccines.

§ An overview of the ongoing vaccine development initiativesfor complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS,malaria and zika virus infection.

§ An analysis of the investments made in this domain, duringthe period between 2015 and 2020 (till March).

§ A case study on contract manufacturing landscape forvaccines, featuring the CMOs engaged in this domain.

§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)

§ Route of Administration

§ Intramuscular

§ Subcutaneous

§ Oral

§ Intravenous

§ Others

 

§ Type of Vaccine

§ Pneumococcal Conjugate Vaccine

§ Human Papilloma Virus Vaccine

§ Rotavirus Vaccine

§ Influenza Vaccine

§ MMR Vaccine

§ Tetanus and Diphtheria Booster Vaccine

§ Varicella Vaccine

§ DTaP-Hib-IPV Vaccine

§ DTaP-HepB-Hib-IPV Vaccine

§ Others

 

§ Type of Vaccine API

§ Live, Attenuated Vaccine

§ Inactivated Vaccine

§ Conjugate Vaccine

§ Subunit Vaccine

§ Toxoid Vaccine

§ Others

§ Target Patient Population

§ Pediatric Patients

§ Adults

 

§ Key Players

§ GlaxoSmithKline

§ Merck

§ Sanofi Pasteur

§ Pfizer

§ Emergent BioSolutions

§ CSL

§ Others

 

§ Key Geographical Regions 

§ North America

§ Europe

§ Asia Pacific

§ Rest of the World 

 

Keycompanies covered in the report

§ Bio Farma

§ Emergent BioSolutions

§ GC Pharma

§ GlaxoSmithKline

§ Janssen

§ Merck

§ Novavax

§ Pfizer

§ Sanofi Pasteur

§ Valneva

 

Formore information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

 

Other Recent Offerings

§  Novelcoronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics inDevelopment

§  NovelVaccine Delivery Devices Market, 2019-2030 [COVID-19 SERIES]

§  VaccineContract Manufacturing Market (2nd Edition), 2019-2030[COVID-19 SERIES]

 

About Roots Analysis

Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com